Timothy J. Underwood
University of Southampton
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Timothy J. Underwood.
Nature Genetics | 2014
Jamie M.J. Weaver; Caryn S. Ross-Innes; Nicholas Shannon; Andy G. Lynch; Tim Forshew; Mariagnese Barbera; Muhammed Murtaza; Chin-Ann J. Ong; Pierre Lao-Sirieix; Mark J. Dunning; Laura Smith; M.L.R. Smith; Charlotte Anderson; Benilton Carvalho; Maria O'Donovan; Timothy J. Underwood; Andrew May; Nicola Grehan; Richard H. Hardwick; Jim Davies; Arusha Oloumi; Sam Aparicio; Carlos Caldas; Matthew Eldridge; Paul A.W. Edwards; Nitzan Rosenfeld; Simon Tavaré; Rebecca C. Fitzgerald
Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barretts esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barretts esophagus (NDBE; n = 66) and high-grade dysplasia (HGD; n = 43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barretts esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.
British Journal of Surgery | 2010
M. Abu Hilal; Timothy J. Underwood; M. Zuccaro; John Primrose; Neil W. Pearce
Laparoscopic surgery for primary colorectal cancer is now commonplace but the uptake of laparoscopic surgery for colorectal liver metastasis (CRLM) has been slow, mainly owing to doubts regarding safety, feasibility and oncological efficiency.
Nature Genetics | 2016
Maria Secrier; Xiaodun Li; Nadeera de Silva; Matthew Eldridge; Gianmarco Contino; Jan Bornschein; Shona MacRae; Nicola Grehan; Maria O'Donovan; Ahmad Miremadi; Tsun-Po Yang; Lawrence Bower; Hamza Chettouh; Jason Crawte; Núria Galeano-Dalmau; Anna M. Grabowska; John Saunders; Timothy J. Underwood; Nicola Waddell; Andrew P. Barbour; Barbara Nutzinger; Achilleas Achilleos; Paul A.W. Edwards; Andy G. Lynch; Simon Tavaré; Rebecca C. Fitzgerald
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.
Gastroenterology | 2015
Claire Palles; Laura Chegwidden; Xinzhong Li; John M. Findlay; Garry Farnham; Francesc Castro Giner; Maikel P. Peppelenbosch; Michal Kovac; Claire L. Adams; Hans Prenen; Sarah Briggs; Rebecca Harrison; Scott Sanders; David MacDonald; Chris Haigh; A. T. Tucker; Sharon Love; Manoj Nanji; John deCaestecker; David Ferry; Barrie Rathbone; Julie Hapeshi; Hugh Barr; Paul Moayyedi; Peter H. Watson; Barbara Zietek; Neera Maroo; Timothy J. Underwood; Lisa Boulter; Hugh McMurtry
Background & Aims Barretts esophagus (BE) increases the risk of esophageal adenocarcinoma (EAC). We found the risk to be BE has been associated with single nucleotide polymorphisms (SNPs) on chromosome 6p21 (within the HLA region) and on 16q23, where the closest protein-coding gene is FOXF1. Subsequently, the Barretts and Esophageal Adenocarcinoma Consortium (BEACON) identified risk loci for BE and esophageal adenocarcinoma near CRTC1 and BARX1, and within 100 kb of FOXP1. We aimed to identify further SNPs that increased BE risk and to validate previously reported associations. Methods We performed a genome-wide association study (GWAS) to identify variants associated with BE and further analyzed promising variants identified by BEACON by genotyping 10,158 patients with BE and 21,062 controls. Results We identified 2 SNPs not previously associated with BE: rs3072 (2p24.1; odds ratio [OR] = 1.14; 95% CI: 1.09–1.18; P = 1.8 × 10−11) and rs2701108 (12q24.21; OR = 0.90; 95% CI: 0.86–0.93; P = 7.5 × 10−9). The closest protein-coding genes were respectively GDF7 (rs3072), which encodes a ligand in the bone morphogenetic protein pathway, and TBX5 (rs2701108), which encodes a transcription factor that regulates esophageal and cardiac development. Our data also supported in BE cases 3 risk SNPs identified by BEACON (rs2687201, rs11789015, and rs10423674). Meta-analysis of all data identified another SNP associated with BE and esophageal adenocarcinoma: rs3784262, within ALDH1A2 (OR = 0.90; 95% CI: 0.87–0.93; P = 3.72 × 10−9). Conclusions We identified 2 loci associated with risk of BE and provided data to support a further locus. The genes we found to be associated with risk for BE encode transcription factors involved in thoracic, diaphragmatic, and esophageal development or proteins involved in the inflammatory response.
The Journal of Pathology | 2015
Timothy J. Underwood; Annette Hayden; Mathieu Derouet; Edwin Garcia; Fergus Noble; Michael J White; Steve Thirdborough; Abbie Mead; Nicholas J. Clemons; Massimiliano Mellone; Chudy Uzoho; John Primrose; Jeremy P. Blaydes; Gareth J. Thomas
Interactions between cancer cells and cancer‐associated fibroblasts (CAFs) play an important role in tumour development and progression. In this study we investigated the functional role of CAFs in oesophageal adenocarcinoma (EAC). We used immunochemistry to analyse a cohort of 183 EAC patients for CAF markers related to disease mortality. We characterized CAFs and normal oesophageal fibroblasts (NOFs) using western blotting, immunofluorescence and gel contraction. Transwell assays, 3D organotypic culture and xenograft models were used to examine the effects on EAC cell function and to dissect molecular mechanisms regulating invasion. Most EACs (93%) contained CAFs with a myofibroblastic (α‐SMA‐positive) phenotype, which correlated significantly with poor survival [p = 0.016; HR 7. 1 (1.7–29.4)]. Primary CAFs isolated from EACs have a contractile, myofibroblastic phenotype and promote EAC cell invasion in vitro (Transwell assays, p ≤ 0.05; organotypic culture, p < 0.001) and in vivo (p ≤ 0.05). In vitro, this pro‐invasive effect is modulated through the matricellular protein periostin. Periostin is secreted by CAFs and acts as a ligand for EAC cell integrins αvβ3 and αvβ5, promoting activation of the PI3kinase–Akt pathway. In patient samples, periostin expression at the tumour cell–stromal interface correlates with poor overall and disease‐free survival. Our study highlights the importance of the tumour stroma in EAC progression. Paracrine interaction between CAF‐secreted periostin and EAC‐expressed integrins results in PI3 kinase–Akt activation and increased tumour cell invasion. Most EACs contain a myofibroblastic CAF‐rich stroma; this may explain the aggressive, highly infiltrative nature of the disease, and suggests that stromal targeting may produce therapeutic benefit in EAC patients.
PLOS Medicine | 2005
Shally Awasthi; Jil Beardmore; Jocalyn Clark; Philip Hadridge; Hardi Madani; Ana Marušić; Gretchen Purcell; Margaret Rhoads; Karen Sliwa-Hähnle; Richard Smith; Tessa Tan-Torres Edejer; Peter Tugwell; Timothy J. Underwood
The International Campaign to Revitalise Academic Medicine (ICRAM) considered current global instabilities and future drivers of change, and then created five scenarios of how academic medicine might look in 2025.
Journal of Gastrointestinal Surgery | 2012
Fergus Noble; Nathan Curtis; Scott Harris; Jamie Kelly; Ian S. Bailey; James Byrne; Timothy J. Underwood
BackgroundOesophagectomy is associated with significant morbidity and mortality. A simple score to define a patients risk of developing major complications would be beneficial.MethodsPatients who underwent upper gastrointestinal resections with an oesophageal anastomosis between 2005 and 2010 were reviewed and formed the development dataset with resections performed in 2011 forming a prospective validation dataset. The association between post-operative C-reactive protein (CRP), white cell count (WCC) and albumin levels with anastomotic leak (AL) or major complication including death using the Clavien–Dindo (CD) classification were analysed by receiver operating characteristic curves. After multivariate analysis, from the development dataset, these factors were combined to create a novel score which was subsequently tested on the validation dataset.ResultsTwo hundred fifty-eight patients were assessed to develop the score. Sixty-three patients (25%) developed a major complication, and there were seven (2.7%) in-patient deaths. Twenty-six (10%) patients were diagnosed with AL at median post-operative day 7 (range: 5–15). CRP (p = 0.002), WCC (p < 0.0001) and albumin (p = 0.001) were predictors of AL. Combining these markers improved prediction of AL (NUn score > 10: sensitivity 95%, specificity 49%, diagnostic accuracy 0.801 (95% confidence interval: 0.692–0.909, p < 0.0001)). The validation dataset confirmed these findings (NUn score > 10: sensitivity 100%, specificity 57%, diagnostic accuracy 0.879 (95% CI 0.763–0.994, p = 0.014)) and a major complication or death (NUn > 10: sensitivity 89%, specificity 63%, diagnostic accuracy 0.856 (95% CI 0.709–1, p = 0.001)).ConclusionsBlood-borne markers of the systemic inflammatory response are predictors of AL and major complications after oesophageal resection. When combined they may categorise a patients risk of developing a serious complication with higher sensitivity and specificity.
Oncotarget | 2016
Christopher J. Hanley; Fergus Noble; Matthew Ward; Marc D. Bullock; Cole R. Drifka; Massimiliano Mellone; Antigoni Manousopoulou; Harvey E. Johnston; Annette Hayden; Stephen M. Thirdborough; Yuming Liu; David M. Smith; Toby Mellows; W. John Kao; Spiros D. Garbis; Alex H. Mirnezami; Timothy J. Underwood; Kevin W. Eliceiri; Gareth J. Thomas
Collagen structure has been shown to influence tumor cell invasion, metastasis and clinical outcome in breast cancer. However, it remains unclear how it affects other solid cancers. Here we utilized multi-photon laser scanning microscopy and Second Harmonic Generation to identify alterations to collagen fiber structure within the tumor stroma of head & neck, esophageal and colorectal cancers. Image segmentation algorithms were then applied to quantitatively characterize these morphological changes, showing that elongated collagen fibers significantly correlated with poor clinical outcome (Log Rank p < 0.05). We used TGF-β treatment to model fibroblast conversion to smooth muscle actin SMA-positive cancer associated fibroblasts (CAFs) and found that these cells induce the formation of elongated collagen fibers in vivo. However, proteomic/transcriptomic analysis of SMA-positive CAFs cultured ex-vivo showed significant heterogeneity in the expression of genes with collagen fibril organizing gene ontology. Notably, stratifying patients according to stromal SMA-positivity and collagen fiber elongation was found to provide a highly significant correlation with poor survival in all 3 cancer types (Log Rank p ≤ 0.003). In summary, we show that increased collagen fiber length correlates with poor patient survival in multiple tumor types and that only a sub-set of SMA-positive CAFs can mediate the formation of this collagen structure.
Gut | 2014
Danielle L. Lavery; Anna M. Nicholson; Richard Poulsom; Rosemary Jeffery; Alia Hussain; Janusz Jankowski; Sebastian Zeki; Hugh Barr; Rebecca Harrison; James J. Going; Sritharan Kadirkamanathan; Peter Davis; Timothy J. Underwood; Marco Novelli; Manuel Rodriguez-Justo; Neil A. Shepherd; Marnix Jansen; Nicholas A. Wright; Stuart A. McDonald
Objective Barretts oesophagus shows appearances described as ‘intestinal metaplasia’, in structures called ‘crypts’ but do not typically display crypt architecture. Here, we investigate their relationship to gastric glands. Methods Cell proliferation and migration within Barretts glands was assessed by Ki67 and iododeoxyuridine (IdU) labelling. Expression of mucin core proteins (MUC), trefoil family factor (TFF) peptides and LGR5 mRNA was determined by immunohistochemistry or by in situ hybridisation, and clonality was elucidated using mitochondrial DNA (mtDNA) mutations combined with mucin histochemistry. Results Proliferation predominantly occurs in the middle of Barretts glands, diminishing towards the surface and the base: IdU dynamics demonstrate bidirectional migration, similar to gastric glands. Distribution of MUC5AC, TFF1, MUC6 and TFF2 in Barretts mirrors pyloric glands and is preserved in Barretts dysplasia. MUC2-positive goblet cells are localised above the neck in Barretts glands, and TFF3 is concentrated in the same region. LGR5 mRNA is detected in the middle of Barretts glands suggesting a stem cell niche in this locale, similar to that in the gastric pylorus, and distinct from gastric intestinal metaplasia. Gastric and intestinal cell lineages within Barretts glands are clonal, indicating derivation from a single stem cell. Conclusions Barretts shows the proliferative and stem cell architecture, and pattern of gene expression of pyloric gastric glands, maintained by stem cells showing gastric and intestinal differentiation: neutral drift may suggest that intestinal differentiation advances with time, a concept critical for the understanding of the origin and development of Barretts oesophagus.
Diseases of The Esophagus | 2013
Fergus Noble; Jamie Kelly; Ian S. Bailey; James Byrne; Timothy J. Underwood
The majority of esophagectomies in Western parts of the world are performed by a transthoracic approach reflecting the prevalence of adenocarcinoma of the lower esophagus or esophagogastric junction. Minimally invasive esophagectomy (MIE) has been reported in a variety of formats, but there are no series that directly compare totally minimally invasive thoracolaparoscopic 2 stage esophagectomy (MIE-2) with open Ivor Lewis (IVL). A prospective single-center cohort study of patients undergoing elective MIE-2 or IVL between January 2005 and November 2010 was performed. Short-term clinicopathologic outcomes were recorded using validated systems. One hundred and six patients (median age 66, range 36-85, 88 M : 18 F) underwent two-stage esophagectomy (53 MIE-2 and 53 IVL). Patient demographics (age, sex, body mass index, American Society of Anesthesiologists grade, tumor characteristics, neoadjuvant chemotherapy, and TNM stage) were comparable between the two groups. Outcomes for MIE-2 and IVL were comparable for anastomotic leak rates (5 [9%] vs. 2 [4%], P= 0.241), resection margin clearance (R0) (43 [81%] vs. 38 [72%], P= 0.253), median lymph node yield (19 vs. 18, P= 0.584), and median length of stay (12 [range 7-91] vs. 12 [range 7-101] days), respectively. Blood loss was significantly less for MIE-2 compared with IVL (median 300 [range 0-1250] mL vs. 400 [range 0-3000] mL, respectively, P= 0.021). MIE-2 in this series of selected patients supports its efficacy, when performed by an experienced minimally invasive surgical team. A well-designed multicenter trial addressing clinical effectiveness is now required.